Ascentage Pharma Group International (NASDAQ:AAPG) Earns Buy Rating from BTIG Research

Ascentage Pharma Group International (NASDAQ:AAPG)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a research note issued on Thursday,Benzinga reports. They currently have a $48.00 price objective on the stock. BTIG Research’s price objective would indicate a potential upside of 109.10% from the stock’s previous close.

A number of other research firms have also commented on AAPG. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Oppenheimer initiated coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target for the company. Finally, Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $48.00.

Ascentage Pharma Group International Price Performance

Shares of NASDAQ:AAPG opened at $22.96 on Thursday. Ascentage Pharma Group International has a 12-month low of $17.56 and a 12-month high of $48.45. The business has a fifty day simple moving average of $24.01 and a 200 day simple moving average of $29.87. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million during the quarter.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Ascentage Pharma Group International during the third quarter worth approximately $96,000. ABC Arbitrage SA acquired a new position in Ascentage Pharma Group International in the third quarter valued at approximately $204,000. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth approximately $383,000. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International during the 2nd quarter worth approximately $391,000. Finally, Tema Etfs LLC bought a new position in shares of Ascentage Pharma Group International during the 2nd quarter worth approximately $610,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.